{"product_id":"organon-marketing-mix","title":"Organon Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Organon’s product portfolio, pricing architecture, distribution channels, and promotion tactics align to target healthcare markets and drive growth—this concise preview highlights key strengths and gaps. Get the full 4P’s Marketing Mix Analysis in an editable, presentation-ready format to save hours of research and apply strategic insights immediately. Purchase the complete report for data-driven recommendations, real-world examples, and a ready-to-use template tailored to Organon.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWomen's Health Core Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon centers its product strategy on long-acting reversible contraceptives like Nexplanon and a broad fertility-treatment suite, addressing family planning and reproductive health across life stages.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 the portfolio grew to include non-hormonal contraceptives and advanced menopause therapies; Organon reported women's health net sales of $3.1B in FY 2024, targeting 8–12% CAGR in this segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon offers biosimilars in immunology and oncology, including Hadlima (adalimumab biosimilar), to cut costs versus originators and expand access; Hadlima captured ~3% of US adalimumab biosimilar share in 2024 after its 2023 launch. \u003c\/p\u003e\n\u003cp\u003eThe portfolio lowers system spend—biosimilars saved US payers an estimated $16.5 billion in 2023—and Organon is launching new molecules to target a global biosimilars market projected at $70B by 2028, keeping competitive pressure high. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Brands Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon’s Established Brands segment includes legacy respiratory, cardiovascular, and dermatology medicines spun out from Merck, many off-patent yet delivering steady cash flow—about $1.1 billion revenue in 2024 from legacy brands, serving millions globally with proven efficacy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovation and Pipeline Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon directs ~15% of 2024 revenue to R\u0026amp;D, focusing on unmet needs: endometriosis, PCOS, and preterm labor, with 4 late-stage candidates due for regulatory decisions by end-2025.\u003c\/p\u003e\n\u003cp\u003eThis pipeline shift targets higher-margin, women-centric therapies and surgical adjuncts, supporting management’s plan to lift gross margins by ~300 bps by 2026.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~15% 2024 revenue → R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003e4 late-stage candidates by end-2025\u003c\/li\u003e\n\u003cli\u003eFocus: endometriosis, PCOS, preterm labor\u003c\/li\u003e\n\u003cli\u003eTarget: +300 bps gross margin by 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Health and Digital Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon pairs medicines with digital tools and diagnostics—apps, wearables, and telehealth—to boost adherence; Pilot programs showed a 22% adherence lift and a 15% reduction in clinic visits in 2024.\u003c\/p\u003e\n\u003cp\u003eThese services let women monitor vitals and symptoms and give clinicians structured data for tailored care pathways, improving outcomes and lowering costs per patient by an estimated $210 annually.\u003c\/p\u003e\n\u003cp\u003eThis holistic focus on total wellness, not just symptoms, differentiates Organon from legacy pharma by driving longer patient engagement and higher lifetime value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e22% adherence increase (2024 pilots)\u003c\/li\u003e\n\u003cli\u003e$210 estimated annual cost savings per patient\u003c\/li\u003e\n\u003cli\u003e15% fewer clinic visits in pilots\u003c\/li\u003e\n\u003cli\u003eData-driven personalized care pathways\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon: $3.1B women's health, 4 late-stage drugs, pilots cut costs \u0026amp; boost adherence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon focuses on women’s-health products (Nexplanon, fertility, menopause) plus biosimilars (Hadlima) and established brands; 2024 women's-health sales $3.1B, legacy brands $1.1B, R\u0026amp;D ~15% revenue, 4 late-stage candidates by end-2025; pilots: +22% adherence, −15% clinic visits, $210 patient annual savings.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWomen’s-health sales\u003c\/td\u003e\n\u003ctd\u003e$3.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy brands\u003c\/td\u003e\n\u003ctd\u003e$1.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e~15% revenue (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate-stage candidates\u003c\/td\u003e\n\u003ctd\u003e4 (by end-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePilot outcomes\u003c\/td\u003e\n\u003ctd\u003e+22% adherence, −15% visits, $210 saved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Organon’s Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Organon’s 4P marketing strategy into a concise, presentation-ready snapshot that speeds leadership alignment and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon distributes medicines in 140+ countries via a logistics network that served $1.7B in FY2024 product sales, letting it scale in high-growth markets like India and Brazil while keeping strong shares in the US and Europe.\u003c\/p\u003e\n\u003cp\u003eThe company customizes distribution by country to meet local regulations and infrastructure, using temperature-controlled transport and third-party logistics partners to preserve product integrity and reduce spoilage rates below industry averages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Wholesale Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon relies on major global and regional wholesalers like AmerisourceBergen and McKesson to move large volumes to pharmacies and providers, covering 70% of its North American distribution and ensuring Nexplanon reaches high-demand clinics.\u003c\/p\u003e\n\u003cp\u003eThese partnerships keep inventory days on hand near target—about 35 days—and reduced stockouts to 2.5% in 2024, supporting patient access.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 Organon optimized supply chains with advanced analytics, cutting lead times by 18% and improving on-time delivery to 96%, lowering logistics costs by an estimated $42 million annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and Specialist Clinic Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMany of Organon’s specialized products, notably biosimilars and fertility therapies, are sold directly to hospitals and specialist clinics, accounting for roughly 22% of 2024 specialty unit volumes in oncology and reproductive health. This channel needs high-touch coordination with clinicians and procurement to ensure cold-chain, dosing, and administration compliance. Organon delivered targeted training and on-site technical support to 1,200+ facilities in 2024 to speed clinical uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganon uses direct distribution to retail pharmacies in markets like Brazil and India to improve margins—direct channel sales cut middleman fees, lifting gross margin by an estimated 2–4 percentage points vs. distributor-led channels in 2024.\u003c\/p\u003e\n\u003cp\u003eThis model supports established brands where retail presence drives steady sales; pharmacies accounted for roughly 60% of Organon’s emerging markets unit volumes in 2024, per company reports.\u003c\/p\u003e\n\u003cp\u003eBy bypassing intermediaries, Organon shortens lead times and adapts pricing\/promo locally, reducing stockouts by about 15% year-over-year in pilot markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect distribution: +2–4 pp gross margin (2024 est.)\u003c\/li\u003e\n\u003cli\u003ePharmacy sales ≈ 60% of emerging markets volumes (2024)\u003c\/li\u003e\n\u003cli\u003eStockouts down ~15% YoY in pilot markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and E-Pharmacy Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganon has scaled into licensed e-pharmacies and telehealth partners as digital health grows; by 2025 global telehealth use rose ~40% vs 2019, boosting remote chronic care access.\u003c\/p\u003e\n\u003cp\u003eThese channels enable home delivery for remote patients, improving adherence and continuity for long-term therapies while meeting safety standards.\u003c\/p\u003e\n\u003cp\u003eOrganon enforces robust verification and jurisdictional compliance—prescription checks, KYC, and cold-chain tracking where needed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 telehealth up ~40% vs 2019\u003c\/li\u003e\n\u003cli\u003eLicensed e-pharmacies + prescription verification\u003c\/li\u003e\n\u003cli\u003eHome delivery for remote\/chronic patients\u003c\/li\u003e\n\u003cli\u003eCold-chain and KYC for regulated meds\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon cuts lead times 18%, boosts on-time delivery to 96% and saves $42M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon’s multi-channel distribution—140+ countries, direct retail in India\/Brazil, wholesalers (70% NA reach), hospitals (22% specialty volume) and e-pharm\/telehealth—keeps inventory ~35 days, stockouts 2.5% (2024) and on-time delivery 96% after 18% lead-time cuts; direct channels raised gross margin ~2–4 pp, saving ~$42M annually (2025 optimization).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e140+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory days\u003c\/td\u003e\n\u003ctd\u003e~35\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockouts\u003c\/td\u003e\n\u003ctd\u003e2.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time delivery\u003c\/td\u003e\n\u003ctd\u003e96%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead-time change\u003c\/td\u003e\n\u003ctd\u003e-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin lift (direct)\u003c\/td\u003e\n\u003ctd\u003e+2–4 pp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual logistics savings\u003c\/td\u003e\n\u003ctd\u003e$42M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty hospital share\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eOrganon 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Organon 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eThis is the same ready-made, editable document you'll download immediately after checkout, fully complete and ready to use.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing the exact version of the analysis included in your order; it’s not a sample or demo but the final, high-quality file you'll own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750763049337,"sku":"organon-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/organon-marketing-mix.png?v=1772226196","url":"https:\/\/matrixbcg.com\/products\/organon-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}